CCDM Risk-Based Monitoring 3

Question 1

What is the primary purpose of a Risk Assessment and Categorization Tool (RACT) in clinical trial planning?

Accepted Answer

To systematically identify, score, and prioritize risks by their likelihood and impact to inform the monitoring strategy

Answer

To assign budget allocations to each clinical site based on enrollment projections

Answer

To evaluate the qualifications of contract research organizations before selection

Answer

To generate automated site close-out letters when a trial is completed

Question 2

In a risk-based monitoring program, what distinguishes a 'critical process' from a 'critical data element'?

Accepted Answer

A critical process is a workflow whose failure could impact subject rights or data integrity; a critical data element is a specific data point whose accuracy is essential to study conclusions

Answer

Critical processes are sponsor activities; critical data elements are site activities

Answer

Critical processes require IRB approval; critical data elements require FDA submission

Answer

There is no meaningful distinction — both terms refer to the same concept in RBM

Question 3

During centralized review, a site shows a consistently low rate of protocol deviations compared to all other sites. How should this be interpreted in a risk-based monitoring framework?

Accepted Answer

An unusually low deviation rate may itself be a signal warranting investigation for potential underreporting

Answer

The site is performing perfectly and requires no further monitoring

Answer

The low deviation rate is a positive KRI and confirms the site needs fewer resources

Answer

The site should be rewarded with a reduced monitoring visit frequency immediately

Question 4

Which of the following represents a valid KRI for detecting data integrity issues at a clinical site?

Accepted Answer

Percentage of electronic data capture queries outstanding beyond 30 days

Answer

Number of study coordinators employed at the site

Answer

Distance between the site and the sponsor's headquarters

Answer

Number of competing clinical trials being conducted at the site

Question 5

How does the TransCelerate Biopharma RBM consortium's approach influence industry practice for risk-based monitoring?

Accepted Answer

It provides voluntary industry-consensus guidance, toolkits, and example KRI libraries that sponsors can adapt to their programs

Answer

It mandates specific KRI values that all sponsors must use by FDA regulation

Answer

It replaces the need for sponsors to write their own monitoring plans

Answer

It restricts monitoring to only centralized approaches, eliminating on-site visits

Question 6

When outsourcing monitoring activities to a CRO in an RBM program, what must the sponsor ensure according to ICH E6(R2)?

Accepted Answer

The sponsor retains ultimate oversight responsibility and must confirm the CRO implements the agreed monitoring plan

Answer

The CRO assumes full regulatory responsibility for the trial's compliance

Answer

All monitoring visits must still be conducted by sponsor employees regardless of CRO involvement

Answer

The CRO must use the same electronic systems as the sponsor's internal team

Question 7

Which best describes how risk-based monitoring documentation should be maintained throughout a clinical trial?

Accepted Answer

Ongoing documentation of signals detected, actions taken, and any protocol-justified modifications to the monitoring plan should be maintained as part of the trial master file

Answer

Documentation is only needed at study startup and final close-out

Answer

KRI thresholds and monitoring strategies are fixed at study start and must not be changed

Answer

Monitoring documentation is the sole responsibility of the clinical sites